History

The preparation called FWGE , developed by Hungarian researchers, has been registered by the National Food and Nutrition Science Institution (Országos Élelmezés- és Táplálkozástudományi Intézet) in the category "special therapeutic purpose formula for patients with tumorous disease" (Registry No: 503; OÉTI 6157/2001); its marketing has been authorized by the National Officer of Pharmaceutist General (Országos Tiszti Főgyógyszerész), OTH/97-46/2002, by notice of the Ministry of Health (Egészségügyi Minisztérium), Health Bulletin (Egészségügyi Közlöny) July 1, 2002. FWGE is manufactured utilizing GMP (Good Manufacturing Practice), under supervision of the National Pharmaceutical Institution (Országos Gyógyszerészeti Intézet), OGYI/1 127-100/38/2003. According to available documentation and peerreviewed publications, FWGE has not shown toxic effects either in acute, sub acute, or chronic toxicological tests. In controlled human studies, FWGE did not have any adverse effects after either 1, 3, or 5 years of application. The preparation has not shown any adverse interaction with cytostatics, hormone formulations and immunological drugs. In the USA, Fermented Wheat Germ Extract (FWGE), the generic description of FWGE , has been affirmed as GRAS (Generally Recognized As Safe) in accordance with Food & Drug Administration procedures, a certification of the safety of food ingredients. Studies have been conducted both in Hungary and abroad to explore the effects of FWGE . 

The favorable clinical effects of the formula can be contributed to the induction of apoptosis, the inhibition of transcetolase, ribonucleotide-reductase, several types of kinase and the cyclooxygenases, the activation of natural killer cells, as well as the induction of the intracellular adhesion molecule (CD54, ICAM-1) expression. Clinical studies with the supportive application of FWGE have been conducted in patients suffering from colorectal cancer, malignant melanoma, lung cancer, pediatric solid tumorous diseases, and head and neck cancers. The results have been published in recognized journals; 18 publications can be found in the Medline database. 

The supportive application of the formula in the complex treatment of tumors of the oral cavity

Three clinical studies have been conducted with FWGE in the supportive treatment of head-, cervicaland oral cavity cancers. 

Ear, Nose and Throat Clinic of Semmelweis University

Based on The Scientific and Research Ethics Committee (ETT-TUKEB) Authorization number 9- 3/1998, the open, observation-based clinical study of FWGE as supportive care in the treatment of patients suffering from head and neck tumors was started in January, 1999 at the Ear, Nose and Throat Clinic of Semmelweis University, under the direction of Professor Ottó Ribári. Fifty patients, primarily with tumors of the larynxand the pharynx, were included in the study. Patients with tumors of the bone, salivary gland and other soft tissues were also included in the study in a small number. The histological diagnosis was squamous cell carcinoma in

80% of the cases. FWGE was consumed daily as a part of the complex oncological treatment, both concurrently and after the surgery, as well as during radio- and chemotherapy. At the end of the three-year-long study it was established that majority of patients taking FWGE experienced no tumor recurrences or metastasis after surgery and radiation, and/or chemotherapy. In some of the patients even the existing recurrences and metastasis regressed. FWGE increased the therapeutic effects of both chemo- and radio-therapy, while significantly reducing the side effects. The appetite of patients taking FWGE improved, and the body weight of cachectic patients increased. They regained their general condition and physical strength (Quality of Life). No side effects were observed in relationship with the application of the formula. In the case of six patients with very advanced malignant tumor of the salivary gland, the application of the formula was started after the surgery and irradiation. After three years, the absence of tumor and metastasis was observed with 5 patients. The advanced tumor of the salivary gland of the sixth patient had already caused a neck metastasis; the patient had undergone surgery and full-dose irradiation treatment. Every sixth week a cytostatic treatment was applied until the end of the cycle, with the concurrent application of FWGE. The further cytostatic treatment was suspended – while applying the formula only – for more than half a year, but no progression was observed despite of this, moreover, the physical strength of the patient had significantly increased and his/her body weight had increased by 5 kg.

 The patients had undergone radical surgeries, and some of them received adjuvant chemotherapy (cisplatin, methotrexate, Bleocin combination) and irradiation treatment (irradiation with dose of 60 Gy). Furthermore, patients in the FWGE group took one dose of FWGE (8.5g FWGE pulvis) per day, suspended 150 ml cold drinking water. The formulation was taken 1 hour before one of the main meals. 45 patients participated in the study; 23 persons (9 males and 14 females) in the FWGE group, and 22 persons (14 males and 8 females) in the control group. There was no statistically significant difference in the ratio of the sexes. The average age of the patients was 55.4 years (29-80 years) in the FWGE group and 62.4 years (41–77 years) in the control group. There was no statistically significant difference in the age distribution between the two groups, either. The distribution by stage is listed in Table 1.The distribution of tumors according to the place of origin (anatomical region): tongue - FWGE: 6, control: 6; gingiva - FWGE: 8, control: 5; oral foundation - FWGE: 6, control: 7; other - FWGE: 3, control: 4. By histology testing: 44 squamous cell carcinoma and 1 adenocarcinoma. Recurrences at the beginning of the study (at recruitment): FWGE group: 4/23 (17.4%); control group: 0/22 (0.0%). There was no significant difference between the two groups, but the prognosis of the FWGE group can be considered worse (Fisher exact test: p = 0.059, at the borderline of significance.) Received chemotherapy: FWGE group: 6/2 3, that is 26.1%; control group: 6/22, that is 27.3%. There was no significant difference between the two groups (p = 0.597). 

Received radiotherapy: FWGE group: 3/23 3, that is 13.0%; control group: 9/22, that is 40.9%. There was a significant difference between the two groups, to the disadvantage of the FWGE group (Fisher exact test: p <0.05). The results of the end-point analysis after one year are shown in Table 2. No side effects were experienced during the application of the formula It had been established that, the continuous application of the formula for 1 year had significantly decreased (by almost one order of magnitude) the progression of diseases (characteristically to the stage of the disease, mainly the recurrences) of patients suffering from stage II and III tumorous diseases of the oral cavity, who had undergone radical surgery and received adjuvant chemotherapy and irradiation treatment as needed. Calculation of the relative risk of progression: The total survival rate of the patients was studied by a five-year follow-up. After five years, 17 patients were alive from the FWGE group (74%), and 10 patients were alive from the control group (45.5%). The difference significance (z- and ÷2-trial: p <0.05). The investigators established that by the long-term application of the supplemental FWGE formula in malignant tumorous diseases of the oral cavity the ratio of local reoccurrences can be significantly decreased and the five-year survival rate can be significantly increased. The investigators suggested that the complex therapeutic protocols applied for malignant tumorous diseases of the oral cavity be supplemented by the supportive treatment with the formula FWGE.